The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate dividends against long-term scientific breakthroughs.
Amgen is a global leader in traditional drug manufacturing with a vast portfolio of approved therapies. In contrast, CRISPR Therapeutics is a pioneer in gene-editing technology, recently launching its first commercial product. This comparison explores which approach offers a more compelling opportunity for your portfolio in 2026.
Amgen develops medicines for heart disease, obesity, and rare diseases among healthcare stocks. Its portfolio includes treatments for inflammatory conditions and various cancers, serving patients in more than 100 countries. The company distributes products primarily through three wholesalers: McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). These three companies accounted for nearly 77% of worldwide gross revenues in 2025. Customer concentration like this adds a layer of risk to the business.
In FY 2025, revenue reached nearly $36.7 billion, representing a growth of approximately 9.9% over the previous year. The company reported a net income of close to $7.7 billion for the same period, indicating a net margin of roughly 21%, an improvement over the 12.2% seen in 2024. These figures reflect the steady demand for its core products despite a shifting regulatory landscape.